Press Releases

Positive results from pivotal Phase 3 REGENERATE study of OCA in patients with liver fibrosis due to NASH New Drug Application (NDA) filing in the U.S. for OCA in NASH projected in the third quarter of 2019   Worldwide Ocaliva net sales of $51.8 million in the first quarter of 2019 representing 47%

NEW YORK , May 01, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2019 financial results prior

OCA significantly improved fibrosis in patients with liver fibrosis due to NASH and demonstrated consistent efficacy across multiple histologic and biochemical parameters REGENERATE data to be presented during the Opening Ceremony of EASL NEW YORK , April 11, 2019 (GLOBE NEWSWIRE) -- Intercept

Multiple additional abstracts evaluating obeticholic acid (OCA) for the treatment of patients with progressive non-viral liver diseases to be presented at the meeting NEW YORK , April 04, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on

NEW YORK , March 05, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be presenting at the

Positive topline results from pivotal Phase 3 REGENERATE study of obeticholic acid in patients with liver fibrosis due to NASH: the largest and first successful pivotal Phase 3 NASH study   Worldwide Ocaliva net sales of $52.9 million in the fourth quarter of 2018 and $177.8 million in the full

NEW YORK , Feb. 20, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its fourth quarter and full year 2018 financial

First and largest successful pivotal Phase 3 study in patients with liver fibrosis due to NASH OCA achieves primary endpoint demonstrating statistically significant improvement in liver fibrosis without worsening of NASH at 18 months (p=0.0002) Intercept intends to file for regulatory approval in

Top-line data from the interim analysis of the Phase 3 REGENERATE trial of obeticholic acid (OCA) in nonalcoholic steatohepatitis (NASH) patients with advanced fibrosis anticipated in Q1 2019 Phase 3 REVERSE trial of OCA in NASH patients with compensated cirrhosis projected to complete enrollment

NEW YORK , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be presenting at the